
Digital Twins Solve Rare Disease Trial Dilemma
Using virtual clones to simulate disease progression could finally solve the recruitment bottleneck that stalls rare disease drug development.
Discover the newest research about AI innovations in 🧪 Drug Discovery.

Using virtual clones to simulate disease progression could finally solve the recruitment bottleneck that stalls rare disease drug development.

An AI giant is moving from writing software code to designing biological molecules, raising both commercial hopes and biosecurity alarms.

By rebuilding proteins backward, drug developers are trying to bypass the human digestive system’s natural defenses.

Regulators are finally letting AI predict drug safety before human trials, signaling a massive shift away from traditional animal testing.

The regulatory bottleneck for AI in drug development is finally beginning to crack.

Generative AI just bypassed decades of traditional chemistry to design a viable antibiotic from scratch, but the real test lies in the clinical pipeline.

Heterocyclic compounds drive pharmaceutical innovation, enhancing therapeutic agents and economic growth. Key insights from PubMed article. 💊📈

New pediatric brain tumor model improves drug testing. Developed by University of Trento and Bambino Gesù Hospital. 🧠💊

Machine learning identifies nucleoside hydrogels for periodontitis treatment, enhancing drug delivery and tissue engineering. 🦷💧

AI tools like YuelDesign, YuelPocket, and YuelBond aim to speed up drug development processes. 💊🤖